ACM
VRTX icon

Ascendant Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Ascendant Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,300
Closed -$375K – 81
2022
Q4 		$375K Sell
1,300
-1,700
-57% -$518K 1.12% 34
2022
Q3 		$869K Hold
3,000
– – 3.63% 11
2022
Q2 		$845K Buy
+3,000
New +$803K 2.5% 17

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ascendant Capital Management's VRTX Position: Q1 2023 in Review

Ascendant Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 1,300 shares — an estimated $375K sold.

Ascendant Capital Management first reported a position in VRTX in Q2 2022 and held it in 3 quarters. The position peaked at $869K in Q3 2022. 1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

  • Ascendant Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Ascendant Capital Management sold 1,300 Vertex Pharmaceuticals shares in Q1 2023, an estimated $375K.
  • Ascendant Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Ascendant Capital Management's Vertex Pharmaceuticals position peaked at $869K in Q3 2022.
  • 1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Ascendant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.